PTGS2 and cancer: Derivative 22 (IC50 = 0.08 ± 0.03 μM, SI = 451) (Figure 5) expressed COX-2 inhibition and also demonstrated prominent activity (IC50 = 1.63 ± 0.97 μM) against the A549 cancer cell line.